Literature DB >> 22210326

The other Achilles' heel of BCR-ABL1.

Kim De Keersmaecker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22210326      PMCID： PMC3248922          DOI： 10.3324/haematol.2011.061002

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

Review 1.  The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

Authors:  Michael Deininger; Elisabeth Buchdunger; Brian J Druker
Journal:  Blood       Date:  2004-12-23       Impact factor: 22.113

2.  Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.

Authors:  Amr R Ibrahim; Richard E Clark; Tessa L Holyoake; Jenny Byrne; Pat Shepherd; Jane F Apperley; Dragana Milojkovic; Richard Szydlo; John Goldman; David Marin
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

3.  Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.

Authors:  Neil P Shah; Dong-Wook Kim; Hagop Kantarjian; Philippe Rousselot; Pedro Enrique Dorlhiac Llacer; Alicia Enrico; Jorge Vela-Ojeda; Richard T Silver; Hanna Jean Khoury; Martin C Müller; Alexandre Lambert; Yousif Matloub; Andreas Hochhaus
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

4.  A myristoyl/phosphotyrosine switch regulates c-Abl.

Authors:  Oliver Hantschel; Bhushan Nagar; Sebastian Guettler; Jana Kretzschmar; Karel Dorey; John Kuriyan; Giulio Superti-Furga
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

5.  Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.

Authors:  Florian Grebien; Oliver Hantschel; John Wojcik; Ines Kaupe; Boris Kovacic; Arkadiusz M Wyrzucki; Gerald D Gish; Sabine Cerny-Reiterer; Akiko Koide; Hartmut Beug; Tony Pawson; Peter Valent; Shohei Koide; Giulio Superti-Furga
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

6.  Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Authors:  Jianming Zhang; Francisco J Adrián; Wolfgang Jahnke; Sandra W Cowan-Jacob; Allen G Li; Roxana E Iacob; Taebo Sim; John Powers; Christine Dierks; Fangxian Sun; Gui-Rong Guo; Qiang Ding; Barun Okram; Yongmun Choi; Amy Wojciechowski; Xianming Deng; Guoxun Liu; Gabriele Fendrich; André Strauss; Navratna Vajpai; Stephan Grzesiek; Tove Tuntland; Yi Liu; Badry Bursulaya; Mohammad Azam; Paul W Manley; John R Engen; George Q Daley; Markus Warmuth; Nathanael S Gray
Journal:  Nature       Date:  2010-01-13       Impact factor: 49.962
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.